Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Accumulated Expenses (2018 - 2023)

Historic Accumulated Expenses for Marker Therapeutics (MRKR) over the last 7 years, with Q2 2023 value amounting to $610000.0.

  • Marker Therapeutics' Accumulated Expenses fell 6102.24% to $610000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $610000.0, marking a year-over-year decrease of 6102.24%. This contributed to the annual value of $750000.0 for FY2022, which is 6875.0% down from last year.
  • As of Q2 2023, Marker Therapeutics' Accumulated Expenses stood at $610000.0, which was down 6102.24% from $454000.0 recorded in Q1 2023.
  • In the past 5 years, Marker Therapeutics' Accumulated Expenses registered a high of $2.4 million during Q4 2021, and its lowest value of $323000.0 during Q4 2019.
  • For the 5-year period, Marker Therapeutics' Accumulated Expenses averaged around $1.1 million, with its median value being $858000.0 (2020).
  • Per our database at Business Quant, Marker Therapeutics' Accumulated Expenses skyrocketed by 42445.82% in 2020 and then crashed by 6875.0% in 2022.
  • Over the past 5 years, Marker Therapeutics' Accumulated Expenses (Quarter) stood at $323000.0 in 2019, then surged by 424.46% to $1.7 million in 2020, then soared by 41.68% to $2.4 million in 2021, then plummeted by 68.75% to $750000.0 in 2022, then dropped by 18.67% to $610000.0 in 2023.
  • Its Accumulated Expenses stands at $610000.0 for Q2 2023, versus $454000.0 for Q1 2023 and $750000.0 for Q4 2022.